CONMED Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Pat Beyer
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 16.6% |
| CEO tenure | no data |
| CEO ownership | 0.03% |
| Management average tenure | 3.5yrs |
| Board average tenure | 9.2yrs |
Recent management updates
Recent updates
Is Now The Time To Look At Buying CONMED Corporation (NYSE:CNMD)?
Jan 01
CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20
Dec 13Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Nov 25CONMED's (NYSE:CNMD) Earnings Are Weaker Than They Seem
Nov 07Earnings Beat: CONMED Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 02Should You Investigate CONMED Corporation (NYSE:CNMD) At US$71.92?
Oct 01Why We're Not Concerned About CONMED Corporation's (NYSE:CNMD) Share Price
Sep 12CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
Aug 15CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price
Jul 17AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation
Jun 21There Is A Reason CONMED Corporation's (NYSE:CNMD) Price Is Undemanding
Jun 01Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching
Apr 18Is CONMED (NYSE:CNMD) Using Too Much Debt?
Mar 28CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%
Feb 15US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results
Feb 03Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?
Jan 08Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects
Dec 18CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt
Nov 30Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business
Oct 28Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?
Sep 22Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?
Aug 24Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly
Jul 28Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?
Jun 08These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively
May 17Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)
Apr 28Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching
Mar 10Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden
Feb 14CONMED Non-GAAP EPS of $0.42 misses by $0.48, revenue of $250.9M misses by $51.58M
Feb 02Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)
Jan 24ConMed: Still Fairly Priced, Turning More Constructive
Dec 09At US$83.60, Is CONMED Corporation (NYSE:CNMD) Worth Looking At Closely?
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$132m |
| Jun 30 2024 | n/a | n/a | US$99m |
| Mar 31 2024 | n/a | n/a | US$82m |
| Dec 31 2023 | US$3m | US$549k | US$64m |
| Sep 30 2023 | n/a | n/a | US$58m |
| Jun 30 2023 | n/a | n/a | US$88m |
| Mar 31 2023 | n/a | n/a | -US$94m |
| Dec 31 2022 | US$4m | US$501k | -US$81m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$68m |
| Dec 31 2021 | US$3m | US$537k | US$63m |
| Sep 30 2021 | n/a | n/a | US$62m |
| Jun 30 2021 | n/a | n/a | US$54m |
| Mar 31 2021 | n/a | n/a | US$13m |
| Dec 31 2020 | US$2m | US$477k | US$10m |
| Sep 30 2020 | n/a | n/a | US$311k |
| Jun 30 2020 | n/a | n/a | US$431k |
| Mar 31 2020 | n/a | n/a | US$34m |
| Dec 31 2019 | US$2m | US$416k | US$29m |
| Sep 30 2019 | n/a | n/a | US$29m |
| Jun 30 2019 | n/a | n/a | US$28m |
| Mar 31 2019 | n/a | n/a | US$31m |
| Dec 31 2018 | US$2m | US$385k | US$41m |
Compensation vs Market: Pat's total compensation ($USD3.30M) is below average for companies of similar size in the US market ($USD5.36M).
Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.
CEO
Pat Beyer (58 yo)
no data
Tenure
US$3,299,311
Compensation
Mr. Patrick J. Beyer, also known as Pat, serves as President and Chief Executive Officer of CONMED Corporation from January 01, 2025 and also serves as Director since January 01, 2025. He served as Chief O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$3.30m | 0.035% $ 722.5k | |
| Executive VP | 7yrs | US$2.87m | 0.00073% $ 15.1k | |
| Advisor | no data | US$7.76m | 0.30% $ 6.3m | |
| Chief Information Officer | no data | no data | 0.00083% $ 17.1k | |
| Executive VP | less than a year | no data | no data | |
| Executive Vice President of Strategy & Corporate Development | 9.7yrs | no data | 0.012% $ 248.1k | |
| Executive VP of Information Technology & CIO | 4.8yrs | no data | no data | |
| Executive Vice President of Human Resources | 2.1yrs | no data | 0.0023% $ 46.9k | |
| President of ConMed Electrosurgery | 20.5yrs | US$572.33k | no data | |
| VP of Tax & Treasurer | 9.8yrs | no data | 0.0043% $ 88.0k | |
| Interim Corporate Controller | less than a year | no data | no data |
3.5yrs
Average Tenure
55yo
Average Age
Experienced Management: CNMD's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$3.30m | 0.035% $ 722.5k | |
| Independent Director | 9.5yrs | US$257.37k | 0.066% $ 1.4m | |
| Independent Director | 9.5yrs | US$264.87k | 0.054% $ 1.1m | |
| Independent Director | 11.5yrs | US$257.37k | 0.031% $ 644.4k | |
| Independent Director | 5.1yrs | US$257.37k | 0.012% $ 238.5k | |
| Independent Chair of the Board | 8.9yrs | US$292.37k | 0.045% $ 930.2k | |
| Independent Director | 10.5yrs | US$249.87k | 0.066% $ 1.4m | |
| Independent Director | 5.3yrs | US$264.87k | 0.017% $ 354.8k |
9.2yrs
Average Tenure
63.5yo
Average Age
Experienced Board: CNMD's board of directors are considered experienced (9.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 23:57 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CONMED Corporation is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | Barclays |
| Travis Steed | BofA Global Research |
| Kristen Stewart | CL King & Associates, Inc. |